Skip to main content

Extending the duration of Covid-19 control measures in England

There will be a lot of disappointment about the 4-week delay to the relaxation of Covid-19 control measures in England until 19 July that was announced today by the Prime Minister. But it is the right decision. A delay of a few weeks allows more people to be fully vaccinated with two doses of a Covid-19 vaccine. The vaccination programme in the UK is progressing well; with 79% of adults in the UK having received one dose of a vaccine and with 57% who have received two doses. But this still leaves many adults unvaccinated, including some people in the 50+ age groups who are at highest risk of serious illness, hospitalisation and death. 

The delta variant in circulation in the UK appears to be more infectious and more likely to result in an illness severe enough to require hospitalisation than other strains of SARS-CoV-2; and now accounts for the vast majority of Covid-19 infections. One dose of a Covid-19 vaccine is less effective in preventing symptomatic infection from the delta strain than other variants (e.g. 33% protection after one dose for the delta variant v. 88% for alpha variant based on data from Public Health England). Two doses still provides good protection (81% protection against the delta variant v. 88% protection against the alpha variant), which is why it is essential to increase the number of fully immunised people before relaxing control measures. Delaying the relaxation of lockdown measures allows time for the NHS to proceed further with its vaccination programme. 

We have seen around a 50% increase the in the number of cases of Covid-19 in the UK in the past week. The positive news is that hospital admissions, although increasing, are at a low level; and that deaths have changed little, remaining at a very low level compared to January 2021. This suggests that vaccines are protecting against more serious illness and confirms the need for eligible people at obtain their Covid-19 vaccination as soon as possible. 

In the longer term, a high level of vaccination in the UK population offers the best route to a more normal society and an end to Covid-19 restrictions. This requires giving the NHS - in particular, general practices and pharmacies - the support they need to deliver vaccinations. If possible, the government also needs to increase the supply of vaccines; particularly the Pfizer and Moderna vaccines as these are the ones used in younger people who now comprise the majority of the unvaccinated adults in the UK. It's also essential to address "vaccine hesitancy" to ensure that vulnerable, older people who have not yet attended for their vaccination appointments do get vaccinated to protect themselves and others.

Comments

Popular posts from this blog

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...

What is the difference between primordial prevention and primary prevention?

Primordial prevention and primary prevention are both crucial strategies for promoting health, but they operate at different levels. Primordial prevention aims to address the root causes of health problems and improve the wider determinants of health. It focuses on preventing the emergence of risk factors in the first place by tackling the underlying social, economic, and environmental determinants of health. This involves broad, population-wide interventions such as: Policies that promote healthy food choices: Think about initiatives like taxing sugary drinks to discourage unhealthy consumption, or providing subsidies for fruits and vegetables to make them more accessible. Urban planning that prioritises well-being: This could include creating walkable neighborhoods with safe cycling routes, ensuring access to green spaces for recreation and relaxation, and designing communities that foster social connections. Social programs that address inequality: Initiatives aimed at reducing pov...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...